Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Core Insights - Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases [3] Company Overview - The company utilizes a platform of GeneTAC gene targeted chimera small molecules to create a new class of therapies aimed at modifying the expression of disease-causing genes [3] - Current clinical-stage programs include DT-216P2 for Friedreich ataxia and DT-168 for Fuchs endothelial corneal dystrophy, with additional programs in myotonic dystrophy type-1 and Huntington's disease [3] - Design Therapeutics is also engaged in discovery efforts for multiple genomic medicines [3] Upcoming Events - Management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on September 4, 2025, at 10:55 a.m. ET in New York [1] - A live webcast of the event will be available on the company's website and archived for at least 30 days [2]